Thus far, BC therapeutics have advanced significantly, especially targeted approaches, such as estrogen receptor (ER) and progesterone receptor (PR) targeting, as well as human epidermal growth factor receptor 2 (ERBB2 or HER2) targeting. Here, ERBB2 is linked to breast cancer.